Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novavax Inc (NVAX)

Novavax Inc (NVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,815,424
  • Shares Outstanding, K 140,404
  • Annual Sales, $ 983,710 K
  • Annual Income, $ -545,060 K
  • 60-Month Beta 2.04
  • Price/Sales 2.15
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NVAX with:

Options Overview Details

View History
  • Implied Volatility 89.58% ( -7.73%)
  • Historical Volatility 80.36%
  • IV Percentile 28%
  • IV Rank 43.26%
  • IV High 187.27% on 05/13/24
  • IV Low 15.11% on 11/28/23
  • Put/Call Vol Ratio 0.39
  • Today's Volume 8,721
  • Volume Avg (30-Day) 20,272
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 370,107
  • Open Int (30-Day) 350,855

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.91
  • Number of Estimates 4
  • High Estimate -0.46
  • Low Estimate -1.18
  • Prior Year -1.26
  • Growth Rate Est. (year over year) +27.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.93 +16.56%
on 08/29/24
14.09 -9.58%
on 08/19/24
-0.22 (-1.70%)
since 08/16/24
3-Month
8.87 +43.63%
on 08/08/24
17.81 -28.47%
on 07/26/24
-1.05 (-7.58%)
since 06/18/24
52-Week
3.53 +260.66%
on 02/05/24
23.86 -46.60%
on 06/06/24
+5.33 (+71.93%)
since 09/18/23

Most Recent Stories

More News
Should You Buy Novavax Stock After This Regulatory Win?

The biotech continues to earn important wins, but is it enough?

MRNA : 69.82 (-3.01%)
BNTX : 115.51 (-7.38%)
JNJ : 166.17 (-0.54%)
PFE : 29.75 (-0.27%)
NVAX : 12.56 (-2.86%)
SNY : 57.47 (+0.98%)
Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?

Regulators recently approved an updated COVID shot from Novavax.

NVAX : 12.56 (-2.86%)
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END

SBFM : 2.99 (+5.65%)
NVAX : 12.56 (-2.86%)
RGNX : 12.54 (-3.17%)
BNTX : 115.51 (-7.38%)
ABBV : 192.90 (-0.28%)
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

SBFM : 2.99 (+5.65%)
NVAX : 12.56 (-2.86%)
RGNX : 12.54 (-3.17%)
BNTX : 115.51 (-7.38%)
ABBV : 192.90 (-0.28%)
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?

Don't be too quick to jump on the Wall Street bandwagon.

SNY : 57.47 (+0.98%)
PFE : 29.75 (-0.27%)
NVAX : 12.56 (-2.86%)
Novavax: Q2 Earnings Snapshot

Novavax: Q2 Earnings Snapshot

NVAX : 12.56 (-2.86%)
Where Will Novavax Be in 5 Years?

Its been a good year so far for the biotech, but how long can it keep the momentum going?

SNY : 57.47 (+0.98%)
MRNA : 69.82 (-3.01%)
NVAX : 12.56 (-2.86%)
Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

/CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-Mâ„¢ adjuvant, announced that it has filed for...

NVAX : 12.56 (-2.86%)
Where Will Novavax Be in 1 Year?

We will know a lot more about the vaccine maker's long-term prospects in 12 months.

NVAX : 12.56 (-2.86%)
SNY : 57.47 (+0.98%)
Is It Too Late to Buy Novavax Stock?

Shares of the vaccine maker are trading up 230% this year.

NVAX : 12.56 (-2.86%)
SNY : 57.47 (+0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple...

See More

Key Turning Points

3rd Resistance Point 14.85
2nd Resistance Point 14.38
1st Resistance Point 13.65
Last Price 12.56
1st Support Level 12.45
2nd Support Level 11.98
3rd Support Level 11.25

See More

52-Week High 23.86
Fibonacci 61.8% 16.09
Fibonacci 50% 13.70
Last Price 12.56
Fibonacci 38.2% 11.30
52-Week Low 3.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar